LIM
BBH icon

Lathrop Investment Management’s VanEck Biotech ETF BBH Stock Holding History

Lathrop Investment Management’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,250
Closed -$303K – 58
2015
Q2 		$303K Buy
+2,250
New +$299K 0.1% 49

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
LFM
Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return

Lathrop Investment Management's BBH Position: Q3 2015 in Review

Lathrop Investment Management sold out of VanEck Biotech ETF (BBH) in Q3 2015, closing a stake of 2,250 shares — an estimated $303K sold.

Lathrop Investment Management first reported a position in BBH in Q2 2015 and held it in 1 quarter. The position peaked at $303K in Q2 2015. 83 funds tracked by Wall St. Rank hold BBH as of Q3 2015.

  • Lathrop Investment Management reported no remaining VanEck Biotech ETF position as of Q3 2015 after selling out during the quarter.
  • Lathrop Investment Management sold 2,250 VanEck Biotech ETF shares in Q3 2015, an estimated $303K.
  • Lathrop Investment Management first reported a position in VanEck Biotech ETF in Q2 2015 and held it in 1 quarter.
  • Lathrop Investment Management's VanEck Biotech ETF position peaked at $303K in Q2 2015.
  • 83 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2015.

Based on Lathrop Investment Management's 13F filing for Q3 2015, filed 19 Oct 2015.